Rezolute to Participate in the Citizens Life Sciences Conference

Rezolute (Nasdaq: RZLT) announced management will participate in the Citizens Life Sciences Conference on March 10-11, 2026 in Miami, FL.

Rhea-AI Summary

Rezolute (Nasdaq: RZLT) announced management will participate in the Citizens Life Sciences Conference on March 10-11, 2026 in Miami, FL.

Management plans one-on-one investor meetings throughout the conference; investors should contact their Citizens representative to schedule meetings with the Rezolute team.

Argus Mar 4 session

+6.15% close to close Open Argus

Details

News Market Reaction – RZLT

On Mar 4, the day this news came out, RZLT closed 6.15% above the previous close.

Data tracked by StockTitan Argus for the Mar 4 session.

Key Figures

Conference dates: March 10-11, 2026

Conference dates

March 10-11, 2026

Citizens Life Sciences Conference in Miami, FL

Historical Context

5 past events · Latest: Feb 12

5 events

1. Feb 12

   Earnings and update

   24h Move

   +5.8%

   Q2 fiscal 2026 results and sunRIZE failure details with program update.

2. Feb 04

   Conference participation

   24h Move

   -7.6%

   Announcement of management attendance at Guggenheim biotech summit with 1:1 meetings.

3. Jan 07

   Clinical insights

   24h Move

   +23.0%

   Further Phase 3 sunRIZE data and expanded access outcomes in tumor HI.

4. Dec 11

   Topline trial data

   24h Move

   -87.2%

   Topline sunRIZE Phase 3 results showing primary and key secondary endpoints not met.

5. Nov 10

   Inducement grant

   24h Move

   +0.8%

   Inducement equity options grant to new employees under Nasdaq Rule 5635(c)(4).

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

hypoglycemia, hyperinsulinism

2 terms

hypoglycemia medical

"focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI)"

Hypoglycemia is a condition where blood sugar falls too low to fuel the body and brain, causing symptoms like shakiness, confusion, sweating or fainting. Think of it as a car running low on gas: systems slow or fail until fuel is restored. Investors care because treatments, devices or drugs that cause or prevent hypoglycemia affect patient safety, regulatory approval, product labeling and market acceptance, which influence a company’s commercial prospects.

hyperinsulinism medical

"treating hypoglycemia caused by all forms of hyperinsulinism (HI)"

Hyperinsulinism is a medical condition in which the body makes too much insulin, causing blood sugar to fall dangerously low. It matters to investors because drugs, devices, or tests that diagnose, manage, or correct this imbalance can lead to clinical trial milestones, regulatory approvals, patents and new sales—much like fixing a broken thermostat restores stable temperature, successful treatments can create significant market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Citizens Life Sciences Conference, taking place March 10-11, 2026, in Miami, FL.

Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Citizens representative.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.

Rezolute Contacts:

Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
cmckim@rezolutebio.com
336-608-9706

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Rezolute (RZLT) participate in the Citizens Life Sciences Conference in 2026?

Rezolute will participate on March 10-11, 2026 at the Citizens Life Sciences Conference. According to Rezolute, management will attend in Miami, FL and hold one-on-one investor meetings during the conference to discuss company developments.

Where is the Citizens Life Sciences Conference that Rezolute (RZLT) will attend on March 10-11, 2026?

The Citizens Life Sciences Conference will be held in Miami, FL on March 10-11, 2026. According to Rezolute, its management team will be onsite to meet investors and participate in scheduled one-on-one meetings throughout the event.

How can investors schedule a meeting with Rezolute (RZLT) at the March 2026 Citizens conference?

Investors should contact their Citizens representative to schedule meetings with Rezolute management. According to Rezolute, one-on-one investor meetings will be arranged through Citizens for attendees seeking time with the company team.

What will Rezolute (RZLT) management do at the Citizens Life Sciences Conference on March 10-11, 2026?

Rezolute management will conduct one-on-one investor meetings throughout the conference. According to Rezolute, these meetings are intended to engage investors directly and discuss company progress and strategy during the Miami event.

Will Rezolute (RZLT) present publicly at the March 2026 Citizens Life Sciences Conference?

Rezolute announced management participation and one-on-one meetings but did not specify a public presentation. According to Rezolute, interested investors should use Citizens contacts to arrange meetings with the company team at the conference.